tpst-1495

TPST-1495 is a first-in-class, orally available small molecule dual antagonist of the prostaglandin E2 (PGE2) receptors EP2 and EP4. By selectively inhibiting these two receptors, TPST-1495 aims to block tumor-promoting and immunosuppressive signaling driven by PGE2, which is implicated in cancer progression and resistance to immunotherapy. Unlike COX inhibitors that affect multiple prostanoids, TPST-1495 specifically targets the tumorigenic pathways while sparing pro-inflammatory prostanoid signaling through EP1 and EP3. Preclinical studies have shown that dual inhibition of EP2/EP4 with TPST-1495 results in greater anti-tumor efficacy and immune activation compared to single receptor antagonists or COX inhibitors. The drug is being developed primarily for familial adenomatous polyposis (FAP), a rare inherited condition predisposing patients to colorectal cancer, as well as for various solid tumors including endometrial cancer and microsatellite stable colorectal cancer[1][2][3][4][7].

Other names

TPST 1495TPST1495TPST-1495